The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
An update on PPAR activation by cannabinoids
Abstract
Some cannabinoids activate the different isoforms of PPARs (α, β and γ), as shown through the use of reporter gene assays, binding studies, selective antagonists and knockout studies. Activation of all isoforms, but primarily PPARα and γ, mediates some (but not all) of the analgesic, neuroprotective, neuronal function modulation, anti‐inflammatory, metabolic, anti‐tumour, gastrointestinal and cardiovascular effects of some cannabinoids, often in conjunction with activation of the more traditional target sites of action such as the cannabinoid CB 1 and CB 2 receptors and the TRPV1 ion channel. PPARs also mediate some of the effects of inhibitors of endocannabinoid degradation or transport. Cannabinoids may be chaperoned to the PPARs by fatty acid binding proteins. The aims of this review are to update the evidence supporting PPAR activation by cannabinoids and to review the physiological responses to cannabinoids that are mediated, and not mediated, by PPAR activation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
eCBs and eCB-like metabolites exert their cellular functions through various molecular mechanisms, including by acting as ligands for transcription factors of the PPAR gene family.
“eCBs and eCB-like metabolites exert their cellular functions through various molecular mechanisms, including by acting as ligands for transcription factors of the PPAR gene family30,31.”
From Interaction of sortilin with apolipoprotein E3 enables neurons to use long-chain fatty acids as alternative metabolic fuel (2025) · cites this paper as [30]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kliewer, S. A., Sundseth, S. S., Jones, S. A., Brown, P. J., Wisely, G. B., Koble, C. S., Devchand, P., Wahli, W., Willson, T. M., Lenhard, J. M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4318 · Cited by 2,164
Esposito, G., Scuderi, C., Valenza, M., Togna, G. I., Latina, V., De Filippis, D., Cipriano, M., Carratù, M. R., Iuvone, T., & Steardo, L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028668 · Cited by 410
Rapid Broad-Spectrum Analgesia through Activation of Peroxisome Proliferator-Activated Receptor-α
LoVerme, J., Russo, R., La Rana, G., Fu, J., Farthing, J., Mattace-Raso, G., Meli, R., Hohmann, A., Calignano, A., & Piomelli, D. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.111385 · Cited by 316
Anandamide induced PPARγ transcriptional activation and 3T3-L1 preadipocyte differentiation
Bouaboula, M., Hilairet, S., Marchand, J., Fajas, L., Fur, G. L., & Casellas, P. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.05.032 · Cited by 298
Costa, B., Comelli, F., Bettoni, I., Colleoni, M., & Giagnoni, G. (2008) · Pain · doi:10.1016/j.pain.2008.06.003 · Cited by 286
Scuderi, C., Steardo, L., & Esposito, G. (2014) · Phytotherapy Research · doi:10.1002/ptr.5095 · Cited by 161
Inhibition of Fatty Acid Binding Proteins Elevates Brain Anandamide Levels and Produces Analgesia
Kaczocha, M., Rebecchi, M. J., Ralph, B. P., Teng, Y.-H. G., Berger, W. T., Galbavy, W., Elmes, M. W., Glaser, S. T., Wang, L., Rizzo, R. C., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094200 · Cited by 142 · cited 5×
“On the other hand, inhibition of FABPs reduces inflammatory pain in mice, and this can be inhibited by CB1 receptor or PPARα antagonists (Kaczocha et al., 2014), suggesting here that the FABP-direct degradation of endocannabinoids can also limit their ability to activate PPARα.”
BackgroundInfluentialFat-induced satiety factor oleoylethanolamide enhances memory consolidation
Campolongo, P., Roozendaal, B., Trezza, V., Cuomo, V., Astarita, G., Fu, J., McGaugh, J. L., & Piomelli, D. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903038106 · Cited by 133
The role of fibrate treatment in dyslipidemia: an overview
Katsiki, N., Nikolic, D., Montalto, G., Banach, M., Mikhailidis, D. P., & Rizzo, M. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319170020 · Cited by 131
Wallace, V. C. J., Segerdahl, A. R., Lambert, D. M., Vandevoorde, S., Blackbeard, J., Pheby, T., Hasnie, F., & Rice, A. S. C. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707326 · Cited by 66
Suppression of fibroblast metalloproteinases by ajulemic acid, a nonpsychoactive cannabinoid acid
Johnson, D. R., Stebulis, J. A., Rossetti, R. G., Burstein, S. H., & Zurier, R. B. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21046 · Cited by 41
Flagged first, then by citations
Research works printed but not linked: 108
- 10.4062/biomolther.2014.137 · DOI
- 10.1111/bph.13348 · DOI
- 10.1111/bph.13352 · DOI
- 10.1111/bph.13347 · DOI
- 10.1111/bph.13354 · DOI
- 10.1124/jpet.110.168237 · DOI
- 10.1111/j.1476-5381.2011.01589.x · DOI
- 10.1007/s00109-008-0305-7 · DOI
- 10.1074/jbc.M702538200 · DOI
- 10.1111/bph.12029 · DOI
- 10.1124/jpet.106.105221 · DOI
- 10.1111/adb.12006 · DOI
- 10.1111/j.1476-5381.2012.02208.x · DOI
- 10.1111/bph.12907 · DOI
- 10.1111/bph.12759 · DOI
- 10.1124/jpet.111.191403 · DOI
- 10.1016/j.tem.2012.03.001 · DOI
- 10.1111/j.1365-2990.2011.01248.x · DOI
- 10.1016/j.ejphar.2011.04.009 · DOI
- 10.1016/j.neuropharm.2012.11.017 · DOI
- 10.1111/j.1365-2982.2008.01248.x · DOI
- 10.1038/npp.2012.25 · DOI
- 10.1016/j.ejphar.2011.11.034 · DOI
- 10.1371/journal.pone.0028159 · DOI
- 10.1155/2013/328797 · DOI
- 10.1189/jlb.0911485 · DOI
- 10.1186/1476-511X-11-51 · DOI
- 10.1074/jbc.M112.371757 · DOI
- 10.1111/j.1476-5381.2011.01444.x · DOI
- 10.1007/s11095-008-9748-3 · DOI
- 10.1074/jbc.M114.618447 · DOI
- 10.1136/gutjnl-2013-305005 · DOI
- 10.1016/j.neuropharm.2012.05.013 · DOI
- 10.1002/jnr.23452 · DOI
- 10.1016/j.amjmed.2011.08.025 · DOI
- 10.1038/nature01921 · DOI
- 10.1016/j.neuropharm.2005.02.013 · DOI
- 10.1523/JNEUROSCI.0036-10.2010 · DOI
- 10.1016/j.biochi.2008.11.003 · DOI
- 10.1136/annrheumdis-2011-200314 · DOI
- 10.1007/s11481-012-9399-3 · DOI
- 10.1074/jbc.M404087200 · DOI · Paper page
- 10.4049/jimmunol.1401844 · DOI
- 10.1111/bph.13368 · DOI
- 10.1111/bph.13106 · DOI
- 10.1007/s11033-013-2741-x · DOI
- 10.1074/jbc.M114.605998 · DOI
- 10.1016/j.neuropharm.2008.04.018 · DOI
- 10.1517/13543784.2014.884708 · DOI
- 10.1038/npp.2015.62 · DOI
- 10.1073/pnas.0901515106 · DOI · Paper page
- 10.1074/jbc.M111.304907 · DOI
- 10.1523/JNEUROSCI.0130-12.2012 · DOI
- 10.1007/s12640-010-9166-2 · DOI
- 10.1074/jbc.M201084200 · DOI · Paper page
- 10.1167/iovs.11-9294 · DOI
- 10.1124/mol.63.5.983 · DOI · Paper page
- 10.1016/j.nbd.2009.09.020 · DOI
- 10.1016/j.lfs.2005.05.012 · DOI
- 10.1111/j.1369-1600.2010.00222.x · DOI
- 10.1016/j.nbd.2014.11.024 · DOI
- 10.1016/j.biopsych.2010.07.009 · DOI
- 10.1101/lm.1145209 · DOI
- 10.1523/JNEUROSCI.3221-08.2008 · DOI
- 10.2174/156802612799436669 · DOI · Paper page
- 10.1016/j.mcn.2008.10.015 · DOI
- 10.1155/2012/728461 · DOI
- 10.1016/j.prostaglandins.2010.12.002 · DOI
- 10.1038/sj.bjp.0707423 · DOI
- 10.1124/jpet.105.095828 · DOI
- 10.1155/2009/425289 · DOI
- 10.1016/j.ejphar.2009.03.010 · DOI
- 10.1016/j.bbrc.2005.09.121 · DOI
- 10.1002/wmts.73 · DOI
- 10.1074/jbc.M115.646885 · DOI
- 10.1007/s00213-008-1399-x · DOI
- 10.1007/s00296-007-0489-0 · DOI
- 10.1186/1742-2094-10-20 · DOI
- 10.1093/nar/gkt1143 · DOI
- 10.1016/j.pnpbp.2014.11.005 · DOI
- 10.1111/j.1398-9995.2009.02254.x · DOI
- 10.1016/j.semcdb.2012.01.003 · DOI
- 10.1007/s12012-015-9332-0 · DOI
- 10.1124/mol.110.070441 · DOI
- 10.1158/1535-7163.MCT-12-0335 · DOI
- 10.1016/j.pbb.2011.11.011 · DOI
- 10.1111/j.1365-2567.2008.02838.x · DOI
- 10.1007/s00213-015-4050-7 · DOI
- 10.1124/jpet.104.065524 · DOI
- 10.1124/mol.105.019117 · DOI
- 10.1016/j.peptides.2013.08.006 · DOI
- 10.1016/j.ejphar.2012.02.049 · DOI
- 10.1038/bjp.2008.335 · DOI
- 10.1016/j.pain.2012.10.018 · DOI
- 10.1016/j.pain.2011.08.010 · DOI
- 10.1111/j.1582-4934.2011.01267.x · DOI
- 10.1038/cddis.2014.376 · DOI
- 10.1186/1742-2094-9-49 · DOI
- 10.1093/cvr/cvv179 · DOI
- 10.1038/sj.bjp.0707478 · DOI
- 10.2131/jts.38.305 · DOI
- 10.1016/j.tox.2014.09.011 · DOI
- 10.1038/cddis.2013.141 · DOI
- 10.1016/j.bcp.2014.07.018 · DOI
- 10.1124/jpet.114.217125 · DOI
- 10.1074/jbc.M114.559062 · DOI
- 10.1523/JNEUROSCI.1165-14.2014 · DOI
- 10.1016/j.neuropharm.2012.03.008 · DOI
Cited by
Sorted by citations
The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases
Lowe, H., Toyang, N., Steele, B., Bryant, J., & Ngwa, W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179472 · Cited by 303
Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years
Maccarrone, M., Di Marzo, V., Gertsch, J., Grether, U., Howlett, A. C., Hua, T., Makriyannis, A., Piomelli, D., Ueda, N., & van der Stelt, M. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000600 · Cited by 183
Greda, A. K., Gomes, J. P., Schmidt-Krueger, V., Zurawska-Plaksej, E., Fritsche-Guenther, R., Rudolph, I.-M., Telugu, N. S., Cömert, C., Kirwan, J., Kunz, S., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01389-5 · Cited by 21
Metadata
- Authors
- O'Sullivan, S. E.
- Affiliations
- School of Medicine, Royal Derby Hospital University of Nottingham
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2016-05-19
- Volume
- 173
- Issue
- 12
- Pages
- 1899-1910
- ISSN
- 0007-1188
- 1476-5381
- Cited by
- 449
- References
- 11
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
